Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | SMARCA4 mutant |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06682806 | Phase II | Pembrolizumab + PRT3789 | A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | Active, not recruiting | USA | ESP | 0 |
| NCT06560645 | Phase I | PRT7732 | A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation | Active, not recruiting | USA | ESP | DEU | AUS | 2 |
| NCT06561685 | Phase I | Carboplatin + LY4050784 + Pembrolizumab + Pemetrexed Disodium LY4050784 Cisplatin + LY4050784 + Pembrolizumab + Pemetrexed Disodium Carboplatin + LY4050784 + Nab-paclitaxel + Pembrolizumab Carboplatin + LY4050784 + Paclitaxel + Pembrolizumab LY4050784 + Pembrolizumab | A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ESP | 1 |
| NCT05687136 | Phase I | M1774 + Peposertib | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and M1774 for Advanced Solid Tumors | Recruiting | USA | 0 |
| NCT03155620 | Phase II | Tazemetostat Tipifarnib Larotrectinib LY3023414 Vemurafenib Selpercatinib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Active, not recruiting | USA | CAN | AUS | 1 |
| NCT05286801 | Phase Ib/II | Atezolizumab + Tiragolumab | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | Active, not recruiting | USA | CAN | AUS | 0 |
| NCT02601950 | Phase II | Tazemetostat | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | Completed | USA | ITA | GBR | FRA | DEU | CAN | BEL | AUS | 1 |
| NCT04611139 | Phase I | Pembrolizumab + Seclidemstat | Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers | Withdrawn | USA | 0 |
| NCT05495464 | Phase I | Cyclophosphamide + Fludarabine Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine Acalabrutinib + Rituximab | A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma | Active, not recruiting | USA | 0 |
| NCT05407441 | Phase Ib/II | Ipilimumab + Nivolumab + Tazemetostat | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | Recruiting | USA | 0 |
| NCT05861050 | Phase Ib/II | Glofitamab-gxbm + Lenalidomide + Obinutuzumab + Venetoclax | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | Recruiting | USA | 0 |
| NCT04416568 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | Active, not recruiting | USA | 0 |
| NCT02114229 | Phase II | Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib Alisertib + Carboplatin + Cyclophosphamide + Vincristine Sulfate Cyclophosphamide + Topotecan Alisertib + Carboplatin + Cyclophosphamide + Etoposide Carboplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Alisertib + Cisplatin + Cyclophosphamide + Vincristine Sulfate | Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT) | Active, not recruiting | USA | 0 |
| NCT02601937 | Phase I | Tazemetostat | A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma | Completed | USA | NLD | ITA | GBR | FRA | DNK | DEU | CAN | AUS | 0 |
| NCT05639751 | Phase I | Docetaxel + PRT3789 PRT3789 | PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation | Completed | USA | NLD | FRA | ESP | 1 |
| NCT06790602 | Phase II | Cemiplimab + Gemcitabine | Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma (SWITCH) | Not yet recruiting | USA | 0 |